Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

Pfizer Cuts Covid-Drug Outlook - Bad News for This Growth Stock

The decision forced a key supplier for a drug component to reduce 2022 guidance.

The Street

Think Tesla's Going Down More? New ETF Rises When Tesla Falls

Looking for more ways to play Tesla stock? In a U.S. industry first, AXS Investments debuted an ETF that tracks just that one popular stock.

Investors Business Daily

The omicron subvariant dominating U.S. COVID-19 cases is more vaccine-resistant

The BA.5 strain represented 65% of cases from July 3 to 9, according to data from the Centers of Disease Control and Prevention.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

COVID-19 vaccines targeting the Omicron variant are on the way — but it could be worth getting a fourth dose now

Omicron is now the dominant strain of COVID-19 around the world and boosters targeting this variant are getting closer to being released.

ABC News

Morningstar: 2 Health-Care Stocks With Dip-Buying Potential

Morningstar has identified two health-care companies it likes that are now trading around fair value and are close to buying range.

The Street

What Are Whales Doing With Pfizer

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 11 strange trades.

Benzinga

Ombudswoman says missing EU Pfizer vaccine deal texts are "wake-up call"

The European Union's ombudswoman criticised the European Commission for failing to find and publish text messages between the executive's president, Ursula von der Leyen, and the head of Pfizer negotiating a massive COVID-19 vaccine deal.

Reuters

Read news from The Economist, FT, and more,
with one subscription

Watchdog reprimands EU executive for failing to share Von der Leyen texts

European Commission ‘gave no good reason’ why its president’s messages with Pfizer were not released

The Guardian - UK

Novavax’s COVID vaccine gets US nod as latest pandemic weapon

Novavax Inc.’s COVID-19 vaccine was cleared by U.S. regulators, giving Americans another tool against the virus as cases start to rise again.

Tribune News Service

These Brazilian besties are inventing an mRNA vaccine as a gift to the world

Pfizer and Moderna have refused to divulge details of how to make their cutting-edge COVID shots. Here's what two scientists — and longtime best friends — are doing about it.

WEKU

US regulators OK new COVID-19 shot option from Novavax

The U.S. is getting another COVID-19 vaccine choice

The Independent UK

Should you book in your second COVID-19 booster? Here's how Israel's fourth dose changed the fight against Omicron

For Australians over 30, a fourth COVID-19 vaccine jab is now available. In Israel, the first country in the world to embrace the second booster, the benefits for some people were dramatic.

ABC News

Why 'Covid Fatigue' Isn't Enough To Keep BioNTech Down; Shares Surge On Upgrade

BioNTech snagged an upgrade Wednesday with an analyst saying "Covid fatigue" has obscured its non-pandemic efforts.

Investors Business Daily

New Google study reveals you've probably been pronouncing 25 brands like Nike, Adidas and Hermès wrong

Over the years, many have taken to search engine Google to find out exactly how to pronounce big name brands correctly.

Chronicle Live

Get all your
news in one place.

100’s of premium titles.
One news app.

360info

Less talk, more action needed to reform IP for all

IP laws are supposed to work to aid pharmaceutical innovation in rich nations. Can a new system support treating illnesses rife in developing economies, too?

Investors Business Daily

Will Novavax's Covid Booster Thesis Play Out? What The Survey Says

Novavax's Covid booster is preemptively gaining steam, according to the July IBD/TIPP Poll. The results come as NVAX stock climbs.

Investors Business Daily

Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them

A handful of pharmaceutical stocks — including Pfizer and Amgen — are either eyeing buy points or have broken out after diving in June.

Tribune News Service

A new COVID-19 foe, a really transmissible one, is emerging

BALTIMORE — If you’ve recently been infected with COVID-19 or know someone infected, and you probably do, you can probably blame BA.5, one of five subvariants of omicron and possibly the most transmissible yet.

Get all your
news in one place.

100’s of premium titles.
One news app.

Reuters

EU backs second COVID booster for over-60s, before variant-adapted vaccines are ready

European Union health agencies on Monday recommended a second COVID-19 booster for everyone over 60, as well as medically vulnerable people, amid a new rise in infections and hospitalisations across Europe.

Tribune News Service

Ask the Pediatrician: What should parents know about COVID-19 vaccine for children under 5?

Q: I have heard that there’s an approved COVID-19 vaccine for children under 5. What do I need to know about it?

Benzinga

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug

Here's a roundup of top developments in the biotech space over the last 24 hours:

Investors Business Daily

Medical Sector Leads New Buys By Top Funds While Big Mac Joins Big Oil

As tech titans like Apple and Nvidia get shunned again, the best mutual funds focus on Big Pharma and biotech stocks.

Zenger

Warning Shots: CureVac Sues BioNTech Over COVID Vax Patents

Pharma giants CureVac are suing Pfizer’s vaccine partner BioNTech over the development of the vaccine credited with saving the world from COVID19.

ABC News

Thinking of mixing and matching COVID-19 vaccine booster shots? There doesn't seem to be much point

Most people will have the Moderna or the Pfizer vaccine for their fourth dose. But the Doherty Institute's head of vaccine and immunisation research says there's practically no difference between them.

Benzinga

The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill

Here's a roundup of top developments in the biotech space over the last 24 hours:

1 … 41 42 43 44

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.